Australian Clinical Labs Ltd
AASX:ACL2.92
AUD
0.00
(0.00%)
ISIN
AU0000148496
Return %
Stock
S&P 500
1Y
15.42
14.20
3Y
7.75
81.12
5Y
-31.93
68.34
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.Company Description
- CEO
- Greg Horan
- Full Time Employees
- 4,500
- Sector
- Health services
- Industry
- Medical/Nursing services
- Address
- 1868-1892 Dandenong Road Clayton VIC Australia 3168
- IPO Date
- May 14, 2021
- Website
- clinicallabs.com.au
- Similar Companies
- Business
- Australian Clinical Labs Limited is an Australian private provider of pathology services established in 2007 and headquartered in Clayton, Victoria. The company operates a network of NATA accredited laboratories across multiple states including Victoria, New South Wales, Western Australia, South Australia, Queensland, and the Northern Territory. Its core offerings encompass a broad range of pathology tests and diagnostic services, including chemical pathology, hematology, histopathology and cytopathology, serology and microbiology, allergy and immunology, molecular cancer testing, genetic carrier screening, antenatal testing, cardiac testing services, veterinary pathology, functional pathology, and clinical trial pathology services. The company also extends skin cancer care through its SunDoctors brand. Recent developments include the acquisition of Medlab Pathology assets in 2021, significantly expanding Australian Clinical Labs’ service capabilities and market presence. The company has focused on strategic acquisitions and partnerships to enhance its testing capabilities and integrate new technologies, supporting a growing customer base comprising doctors, specialists, hospitals, corporate clients, and patients. In 2025, Australian Clinical Labs strengthened its cybersecurity posture by appointing a new Information Security Officer and advancing its NIST cybersecurity compliance framework. The company has also faced operational challenges related to cybersecurity, including a Federal Court penalty of AU$5.8 million in 2025 regarding a data breach incident linked to Medlab Pathology. Australian Clinical Labs generated total revenue of approximately AUD 743 million in 2025 and employs around 4,700 personnel. It continues to pursue expansion through accretive acquisitions targeting both domestic and strategic adjacent markets, maintaining a comprehensive pathology service footprint across Australia’s major regions. The company remains focused on improving patient experience and service quality while enhancing digital and security capabilities. The company serves diverse market segments in the healthcare industry, including molecular diagnostics for cancer, obstetrics and gynecology, pharmacogenetics, gastroenterology, commercial drug and alcohol testing, and veterinary services. Australian Clinical Labs is listed on the Australian Securities Exchange (Ticker: ACL) and operates within the Health Care Providers and Services sector. This comprehensive service portfolio combined with recent strategic acquisitions and reinforced cybersecurity governance highlights Australian Clinical Labs Limited’s commitment to growth and innovation in the Australian pathology services market.